Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00228-012-1432-1PMID 23097010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.

  2011cited by this paper
• The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.

  2011cited by this paper
• Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.

  2010cited by this paper
• Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II

  2010cited by this paper
• Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I

  2010cited by this paper
• Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase

  2010cited by this paper
• Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.

  2009cited by this paper
• The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

  2009cited by this paper
• Structure and Function of an NADPH-Cytochrome P450 Oxidoreductase in an Open Conformation Capable of Reducing Cytochrome P450*

  2009cited by this paper
• Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations

  2008cited by this paper
• Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

  2008cited by this paper
• Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients

  2008cited by this paper
• Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.

  2008cited by this paper
• P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity

  2008cited by this paper
• P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.

  2008cited by this paper
• Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase

  2007cited by this paper
• Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.

  2007cited by this paper
• Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

  2006cited by this paper
• EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO

  2006cited by this paper
• Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects

  2006cited by this paper
• Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry.

  2006cited by this paper
• Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.

  2006cited by this paper
• Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living‐donor liver transplant recipients

  2006cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002influential reference
• NADPH-Cytochrome P450 Oxidoreductase

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• The genetic determinants of the CYP3A5 polymorphism.

  2001cited by this paper

• A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions

  2025cites this paper
• Safety, Tolerability, Pharmacokinetics, and Effects of Gene Polymorphisms on Furaprevir (TG-2349), a Novel Hepatitis C Inhibitor: A Randomized Phase I Study

  2025cites this paper
• Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics

  2024cites this paper
• A descriptive study of the single-nucleotide polymorphisms known to affect the Tacrolimus trough concentration per dose, among a population of kidney failure patients in a tertiary hospital in Ghana

  2024cites this paper
• Improving prediction of tacrolimus concentration using a combination of population pharmacokinetic modeling and machine learning in chinese renal transplant recipients

  2024cites this paper
• Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs

  2023cites this paper
• Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.

  2023cites this paper
• Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study

  2023cites this paper
• Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro

  2022cites this paper
• Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population

  2022cites this paper
• Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes

  2022cites this paper
• Impact of POR*28 Variant on Tacrolimus Pharmacokinetics in Kidney Transplant Patients with Different CYP3A5 Genotypes.

  2022cites this paper
• Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial

  2021cites this paper
• Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling

  2021cites this paper
• Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients—A Population Model Approach

  2021cites this paper
• Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients.

  2020cites this paper
• CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy.

  2020cites this paper
• CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review

  2019cites this paper
• Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation

  2019cites this paper
• CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria

  2019cites this paper
• Model based dosing of tacrolimus after renal transplantation

  2019cites this paper
• CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.

  2018cites this paper
• The Pharmacogenetics of Immune-Modulating Therapy.

  2018cites this paper
• Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation

  2018cites this paper
• CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

  2018cites this paper
• Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.

  2018cites this paper
• Effect of P450 Oxidoreductase Polymorphisms on the Metabolic Activities of Ten Cytochrome P450s Varied by Polymorphic CYP Genotypes in Human Liver Microsomes

  2018cites this paper
• Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia

  2017cites this paper
• Association of CYP3A5 and POR polymorphisms with the maintenance tacrolimus dosage requirement in Thai recipients of kidney transplants

  2017cites this paper
• Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients

  2017cites this paper
• Associations of cytochrome P450 oxidoreductase genetic polymorphisms with smoking cessation in a Chinese population

  2016cites this paper
• Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs

  2016cites this paper
• The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.

  2016cites this paper
• The POR rs1057868–rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients

  2016cites this paper
• Pharmacogenetics of Immunosuppressants in Solid Organ Transplantation: Time to Implement in the Clinic

  2016cites this paper
• Relationships of Selected CYP and ABCB1 Single Nucleotide Polymorphisms and Patient Characteristics with the Pharmacokinetics of Twice Daily Tacrolimus and Advagraf® in Renal Transplant Recipients

  2016cites this paper
• Pharmacogenomics Aspect of Immunosuppressant Therapy

  2016cites this paper
• Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations

  2016cites this paper
• Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation

  2015cites this paper
• Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population

  2015cites this paper
• Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus

  2015cites this paper
• Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.

  2015cites this paper
• The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.

  2015cites this paper
• Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.

  2015influential citation
• Multigene predictors of tacrolimus exposure in kidney transplant recipients.

  2015cites this paper
• Genetic and metabolic studies towards personalized conditioning regimen prior to stem cell transplantation

  2014influential citation
• The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

  2014cites this paper
• Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients

  2014cites this paper
• Pharmacogenomics of human P450 oxidoreductase

  2014cites this paper
• Role of pharmacogenomics in dialysis and transplantation

  2014cites this paper
• POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.

  2014cites this paper
• CYP3A5*3 and POR*28 Genetic Variants Influence the Required Dose of Tacrolimus in Heart Transplant Recipients

  2014cites this paper
• Functional Gene Variants of CYP3A4

  2014cites this paper
• Pharmacogenomics of human P 450 oxidoreductase

  2014cites this paper
• Highlights from the latest articles in pharmacogenomics of solid organ transplantation.

  2014cites this paper
• Challenges in pharmacogenetics

  2013cites this paper
• PharmGKB summary: cyclosporine and tacrolimus pathways

  2013cites this paper
• NADPH P450 oxidoreductase: structure, function, and pathology of diseases.

  2013cites this paper
• From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.

  2013cites this paper
• Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

  2013cites this paper
• Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients

  2013influential citation
• Farmakokinetisk betydning av sekvensvarianter i CYP3A4, CYP3A5, POR og PPARA

  2013influential citation
• EUR Research

  year unknowncites this paper